【US Stock Market Movement】Vaxcyte surged on October 9: Accelerated cancer vaccine development + pneumonia vaccine

Vaxcyte’s Surge on October 9 Explained

Keywords: Cancer vaccine acceleration, pneumonia vaccine

1. On October 9, reports indicated that the U.S. National Institutes of Health plans to accelerate cancer vaccine research. The share prices of several vaccine developers rose, with Vaxcyte increasing by 6.98% that day; the company is primarily engaged in clinical-stage vaccine research and development, and related sector news served as an external catalyst.

2. On October 5, the company announced topline data from the VAX-31 adult phase III OPUS-1 trial, showing that all pre-set primary endpoints were met across all age groups. Among adults aged 50 and above, all 28 shared serotypes met the non-inferiority standard, while the 3 unique serotypes and cross-reactive serotype 20B met the superiority standard. VAX-31 is a 31-valent pneumococcal conjugate vaccine, and the company’s pipeline is targeting a market of approximately $8.5 billion.

(Disclaimer: This content is collated and generated by AI technology based on publicly available information. It is for reference only and does not constitute investment advice.)